IP Library Granted Patent US 10,842,786
Granted Patent B2
US 10,842,786 · App. 15/494,514 · Granted Nov 24, 2020

Chewing gum composition comprising cannabinoids and nicotine

Inventors: Lekhram Changoer (Ridderkerk, NL); George Anastassov (New York, NY)
Assignee: APIRx Pharmaceutical USA, LLC
A61K31/455A61K9/0058A61K31/05A61K31/352A61K47/585
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,842,786
App. No.
15/494,514
Granted
Nov 24, 2020
Kind
B2
Abstract

A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and nicotine during chewing. Methods to provide tobacco and/or cannabis smoking cessation using the chewing gum composition according to this invention are also provided.

Claims (21)

1. A method to treat or alleviate tobacco smoking in a mammal in need thereof, comprising administering to the mammal a chewing gum composition comprising:

0.1 to 1% by weight of at least one cannabinoid;

0.3 to 1% by weight of nicotine polacrilex;

25 to 95% by weight of a gum base;

1 to 10% by weight of at least one flavoring agent selected from the group consisting of peppermint, cinnamon, watermelon, and spearmint; and

1 to 35% by weight of isomalt,

wherein the at least one cannabinoid is provided in encapsulated form, and

wherein the encapsulated form comprises beads formed from a cannabinoid and liquid excipient emulsion absorbed into silica gel.

2. The method of claim 1 , wherein the mammal receives the chewing gum administration 1 to 12 times a day.

3. The method of claim 1 , wherein the at least one cannabinoid is provided in combination with microcrystalline cellulose derivatives.

4. The method of claim 1 , wherein the at least one cannabinoid is cannabidiol.

5. The method of claim 1 , wherein the chewing gum composition further comprises at least one softener present at 2 to 7% by weight of the chewing gum composition.

6. The method of claim 5 , wherein the softener is glycerin.

7. The method of claim 5 , wherein the chewing gum composition further comprises at least one buffering agent selected from the group consisting of acetates, glycinates, phosphates, carbonates, glycerophosphates, citrates, and borates.

8. The method of claim 7 , wherein the at least one buffering agent is present at 0.5 to 5% by weight of the chewing gum composition.

9. The method of claim 7 , wherein the chewing gum composition further comprises at least one preservative.

10. The method of claim 9 , wherein the preservative is citric acid.

11. The method of claim 9 , wherein the chewing gum composition further comprises at least one pharmaceutically acceptable excipient selected from the group consisting of fillers, disintegrants, binders, and lubricants.

12. The method of claim 11 , wherein the chewing gum composition further comprises silicon dioxide or magnesium stearate.

13. The method of claim 12 , wherein the chewing gum composition further comprises at least one anti-oxidant selected from the group consisting of ascorbyl palmitate and sodium ascorbate.

14. The method of claim 13 , wherein the chewing gum composition further comprises water.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: AXIM BIOTECHNOLOGIES, INC.
To: APIRX PHARMACEUTICAL USA, LLC
Reel/Frame 052752/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2017
From: ANASTASSOV, GEORGE E; CHANGOER, LEKHRAM
To: AXIM BIOTECHNOLOGIES, INC.
Reel/Frame 042192/0167 →
Continuity (2)
Provisional Application 62328467 · Apr 27, 2016
Related Publication 20170312261A1 · Nov 2, 2017